Jade Biosciences, Inc. (JBIO)
19.83
-1.57
(-7.34%)
USD |
NASDAQ |
Sep 03, 16:00
19.83
0.00 (0.00%)
After-Hours: 20:00
Jade Biosciences Enterprise Value : 899.53M for Sept. 2, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 02, 2026 | 899.53M |
| September 01, 2026 | 875.37M |
| August 31, 2026 | 896.98M |
| August 28, 2026 | 863.93M |
| August 27, 2026 | 892.53M |
| August 26, 2026 | 895.08M |
| August 25, 2026 | 927.49M |
| August 24, 2026 | 895.08M |
| August 21, 2026 | 895.71M |
| August 20, 2026 | 888.72M |
| August 19, 2026 | 972.62M |
| August 18, 2026 | 1.036B |
| August 17, 2026 | 1.030B |
| August 14, 2026 | 1.110B |
| August 13, 2026 | 1.053B |
| August 12, 2026 | 1.015B |
| August 11, 2026 | 959.90M |
| August 10, 2026 | 920.50M |
| August 07, 2026 | 935.12M |
| August 06, 2026 | 952.91M |
| August 05, 2026 | 918.59M |
| August 04, 2026 | 896.35M |
| August 03, 2026 | 756.52M |
| July 31, 2026 | 794.66M |
| July 30, 2026 | 810.55M |
| Date | Value |
|---|---|
| July 29, 2026 | 769.24M |
| July 28, 2026 | 791.48M |
| July 27, 2026 | 807.37M |
| July 24, 2026 | 815.63M |
| July 23, 2026 | 786.40M |
| July 22, 2026 | 801.01M |
| July 21, 2026 | 844.23M |
| July 20, 2026 | 789.57M |
| July 17, 2026 | 865.21M |
| July 16, 2026 | 841.05M |
| July 15, 2026 | 928.76M |
| July 14, 2026 | 895.71M |
| July 13, 2026 | 893.17M |
| July 10, 2026 | 870.93M |
| July 09, 2026 | 968.17M |
| July 08, 2026 | 971.34M |
| July 07, 2026 | 966.26M |
| July 06, 2026 | 893.17M |
| July 02, 2026 | 906.52M |
| July 01, 2026 | 925.58M |
| June 30, 2026 | 951.64M |
| June 29, 2026 | 780.43M |
| June 26, 2026 | 775.00M |
| June 25, 2026 | 765.62M |
| June 24, 2026 | 770.06M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Perspective Therapeutics, Inc. | 120.75M |
| Cue Biopharma, Inc. | 132.40M |
| Praxis Precision Medicines, Inc. | 9.223B |
| Opus Genetics, Inc. | 315.18M |
| Faeth Therapeutics, Inc. | 831.50M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -55.76M |
| Total Expenses (Quarterly) | 55.76M |
| EPS Diluted (Quarterly) | -0.7569 |
| Earnings Yield | -13.18% |
| Normalized Earnings Yield | -13.18 |